Dr. Premal H. Thaker, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
4921 Parkview Pl, Div Obgyn Gynecologic Oncology, Ste 13c
Saint Louis, MO 63110
- Medicare participating
At a glance
- Years since graduation
- 29
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 249
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
MO license 2006013538
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Missouri Baptist Medical Center Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Barnes-Jewish St Peters Hospital Saint Peters, MO
- Alton Memorial Hospital Alton, IL
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 249
- Services billed
- 21,796
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 196 | 90 |
| Established patient office or other outpatient visit, 20-29 minutes | 129 | 103 |
| Administration of chemotherapy into vein, 1 hour or less | 56 | 12 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 50 | 27 |
| Established patient office or other outpatient visit, 40-54 minutes | 46 | 29 |
| New patient office or other outpatient visit, 45-59 minutes | 38 | 38 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 36 | 22 |
| Exam of external female genitals using an endoscope | 19 | 14 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 19 | 18 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 17 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ondansetron Hcl Other prescribers in Saint Louis, MO | 59 |
| Prochlorperazine Maleate Other prescribers in Saint Louis, MO | 56 |
| Dexamethasone Other prescribers in Saint Louis, MO | 55 |
| Gabapentin Other prescribers in Saint Louis, MO | 47 |
| Lorazepam Other prescribers in Saint Louis, MO | 38 |
| Oxycodone Hcl Other prescribers in Saint Louis, MO | 36 |
| Eliquis (apixaban) Other prescribers in Saint Louis, MO | 29 |
| Letrozole Other prescribers in Saint Louis, MO | 26 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Saint Louis, MO | 21 |
| Estradiol Other prescribers in Saint Louis, MO | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 63 payments worth $50,640 in total to this clinician.
| GlaxoSmithKline, LLC. | $18,805 |
|---|---|
| Incyte Corporation | $8,904 |
| Corcept Therapeutics | $6,917 |
| AstraZeneca UK Limited | $5,480 |
| BioNTech SE | $2,760 |
| AbbVie Inc. | $2,609 |
| Daiichi Sankyo Inc. | $2,584 |
| Olympus Winter & Ibe GmbH | $875 |
| Consulting Fee | $40,784 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,600 |
| Food and Beverage | $1,696 |
| Travel and Lodging | $1,560 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Apr 2, 2025 | Consulting Fee | $9,100 |
| Incyte Corporation Jul 30, 2025 | Consulting Fee | $6,210 |
| AstraZeneca UK Limited Apr 22, 2025 | Consulting Fee | $5,480 |
| Corcept Therapeutics May 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,000 |
| GlaxoSmithKline, LLC. May 22, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $2,800 |
| GlaxoSmithKline, LLC. Sep 4, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $2,800 |
| Corcept Therapeutics Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,600 |
| BioNTech SE Jan 20, 2025 | Consulting Fee | $2,600 |
| GlaxoSmithKline, LLC. Nov 11, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $2,400 |
| AbbVie Inc. Oct 31, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $2,400 |
All 29 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Nov 14, 2025 | Consulting Fee | $1,060 |
| GlaxoSmithKline, LLC. Nov 11, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $2,400 |
| AbbVie Inc. Oct 31, 2025 | Consulting Fee ELAHERE · ONCOLOGY | $2,400 |
| Corcept Therapeutics Oct 20, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,600 |
| Incyte Corporation Oct 20, 2025 | Travel and Lodging travel to BERLIN, Germany | $13.40 |
| GlaxoSmithKline, LLC. Sep 4, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $2,800 |
| Caris Mpi, Inc. Sep 4, 2025 | Consulting Fee MI CANCER SEEK · ONCOLOGY | $75.00 |
| Incyte Corporation Jul 30, 2025 | Consulting Fee | $6,210 |
| Incyte Corporation Jul 16, 2025 | Travel and Lodging travel to Savannah, GA | $233 |
| Incyte Corporation Jul 16, 2025 | Travel and Lodging travel to Savannah, GA | $209 |
| Incyte Corporation Jul 16, 2025 | Travel and Lodging travel to Savannah, GA | $209 |
| Incyte Corporation Jul 16, 2025 | Travel and Lodging travel to Savannah, GA | $41.00 |
| Incyte Corporation Jul 15, 2025 | Travel and Lodging travel to Savannah, GA | $572 |
| Caris Mpi, Inc. Jul 15, 2025 | Consulting Fee MI CANCER SEEK · ONCOLOGY | $400 |
| Incyte Corporation Jul 15, 2025 | Travel and Lodging travel to Savannah, GA | $209 |
| Incyte Corporation Jul 15, 2025 | Travel and Lodging travel to Savannah, GA | $14.99 |
| Caris Mpi, Inc. Jul 10, 2025 | Consulting Fee MI CANCER SEEK · ONCOLOGY | $100 |
| Caris Mpi, Inc. Jun 10, 2025 | Consulting Fee MI CANCER SEEK · ONCOLOGY | $300 |
| GlaxoSmithKline, LLC. Jun 6, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $1,600 |
| Merck Sharp & Dohme LLC Jun 1, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Chicago, IL | $31.50 |
| Corcept Therapeutics May 30, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,000 |
| Corcept Therapeutics May 30, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $26.26 |
| GlaxoSmithKline, LLC. May 22, 2025 | Consulting Fee JEMPERLI · ONCOLOGY | $2,800 |
| AstraZeneca UK Limited Apr 22, 2025 | Consulting Fee | $5,480 |
| Olympus Winter & Ibe GmbH Apr 11, 2025 | Consulting Fee ENDOEYE FLEX DEFLECTABLE VIDEOSCOPE · Surgical Endoscopy | $875 |
| GlaxoSmithKline, LLC. Apr 2, 2025 | Consulting Fee | $9,100 |
| Daiichi Sankyo Inc. Mar 19, 2025 | Consulting Fee | $646 |
| Daiichi Sankyo Inc. Mar 12, 2025 | Consulting Fee | $1,938 |
| BioNTech SE Jan 20, 2025 | Consulting Fee | $2,600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $111,657 in research payments for these studies, mostly to the institutions running them.
- A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Daiichi Sankyo Inc. · Active, not recruiting · NCT04707248 - Multicenter multi cohort open label Ph2 study of biomarker driven therapies for recurrent R OC pat
Genentech, Inc. - First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie Inc. · Active, not recruiting · NCT05527184 - A randomized openlabel phase 3 trial of tisotumab vedotin vs investigators choice chemotherapy in second or thirdline recurrent or metastatic cervical cancer
Pfizer Inc. - RAMP 201 - GOG-3052
Verastem, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.